open access

Vol 11, No 3 (2007)
Prace oryginalne
Published online: 2007-05-31
Get Citation

Role of aldosterone and bradykinin in pathogenesis of left ventricular hypertrophy in patients with primary hypertension

Wojciech Tanecki, Wojciech Kosmala, Adam Spring, Maria Witkowska
Nadciśnienie tętnicze 2007;11(3):223-231.

open access

Vol 11, No 3 (2007)
Prace oryginalne
Published online: 2007-05-31

Abstract


Background Left ventricular hypertrophy (LVH) as a result of hypertension (HT) is a relevant risk factor for cardiovascular complications. The aim of the study was to assess the role of aldosterone and bradykinin in the pathogenesis of LVH in patients in different stages of HT.
Material and methods The investigations were carried out in 100 hypertensive patients (56 male, 44 female) including 34 patients with mild, 45 with moderate, 21 with severe HT. 31 healthy individuals served as controls. Each subject underwent echocardiographic examination and evaluation of aldosterone serum (ALDO) and bradykinin plasma concentration (BRADY) by radioimmunoassay.
Results Left ventricular hypertrophy was found in 48 patients. ALDO and BRADY were significantly higher in hypertensives with LVH than in the group without LVH. In multivariate analysis ALDO as well as BRADY correlated positively and independently with LVM and LVMI only in the group of severe HT. Independent correlations between BRADY and left ventricular ejection fraction (EF) in the whole group of HT as well as in the control group HT were observed.
Conclusions The results of the study indicate the role of aldosterone in the process of LVH. The role of bradykinin as a part of neurohumoral counterregulation in cardiac remodelling is also possible.

Abstract


Background Left ventricular hypertrophy (LVH) as a result of hypertension (HT) is a relevant risk factor for cardiovascular complications. The aim of the study was to assess the role of aldosterone and bradykinin in the pathogenesis of LVH in patients in different stages of HT.
Material and methods The investigations were carried out in 100 hypertensive patients (56 male, 44 female) including 34 patients with mild, 45 with moderate, 21 with severe HT. 31 healthy individuals served as controls. Each subject underwent echocardiographic examination and evaluation of aldosterone serum (ALDO) and bradykinin plasma concentration (BRADY) by radioimmunoassay.
Results Left ventricular hypertrophy was found in 48 patients. ALDO and BRADY were significantly higher in hypertensives with LVH than in the group without LVH. In multivariate analysis ALDO as well as BRADY correlated positively and independently with LVM and LVMI only in the group of severe HT. Independent correlations between BRADY and left ventricular ejection fraction (EF) in the whole group of HT as well as in the control group HT were observed.
Conclusions The results of the study indicate the role of aldosterone in the process of LVH. The role of bradykinin as a part of neurohumoral counterregulation in cardiac remodelling is also possible.
Get Citation

Keywords

aldosterone; bradykinin; hypertension; left ventricular hypertrophy

About this article
Title

Role of aldosterone and bradykinin in pathogenesis of left ventricular hypertrophy in patients with primary hypertension

Journal

Arterial Hypertension

Issue

Vol 11, No 3 (2007)

Pages

223-231

Published online

2007-05-31

Bibliographic record

Nadciśnienie tętnicze 2007;11(3):223-231.

Keywords

aldosterone
bradykinin
hypertension
left ventricular hypertrophy

Authors

Wojciech Tanecki
Wojciech Kosmala
Adam Spring
Maria Witkowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl